(Q43433131)

English

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

scientific article published on 3 October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hans M Westgeest

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Inge M. Van Oort

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Michel D Wissing

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Jules L L M Coenen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Pieter van den Berg

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Alfons J M van den Eertwegh

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Monique M Bos

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

André M Bergman

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Paul Hamberg

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Albert J Ten Tije

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Maartje Los

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Martijn P J K Lolkema

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Ronald de Wit

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hans Gelderblom

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

0 references

publication date

3 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

136

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

E760-72

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

European cancer mortality predictions for the year 2011.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Preclinical evaluation of new taxoids

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29231

21 January 2018

Identifiers

10.1002/IJC.29231

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25242736%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43433131&oldid=1612976735"